Abstract

The present application relates to the field of biomedicine, and in particular to a macrocyclic pyrazolopyrimidine compound which has better immunomodulatory activity and selectivity. The present invention further provides a use of the macrocyclic pyrazolopyrimidine compound for preventing or treating a TLR7-related disease, and a use as a vaccine adjuvant, a photodynamic therapeutic agent, and a drug conjugate.

IPC Classes  ?

• C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/20 - Antivirals for DNA viruses
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The present application relates to the field of biological medicine, and particularly relates to small-molecule polyaryl-containing macrocyclic compounds which have better immunoregulation activity. Further provided in the present invention are the use of the small-molecule polyaryl-containing macrocyclic compounds in preventing or treating TLR7-related diseases, and the uses of same as vaccine adjuvants, photodynamic therapeutic agents and drug conjugates.

IPC Classes  ?

• C07D 498/18 - Bridged systems
• C07D 487/04 - Ortho-condensed systems
• C07D 498/16 - Peri-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 31/12 - Antivirals

Abstract

The present application relates to the field of biomedicine, and particularly relates to a small-molecule phosphorus-containing or sulfur-containing macrocyclic pyrazolopyrimidine compound, which has better immunomodulatory activity. Also provided in the present invention is the use of the small-molecule phosphorus-containing or sulfur-containing macrocyclic pyrazolopyrimidine compound in the prevention or treatment of TLR7-related diseases, and the use thereof as a vaccine adjuvant, a photodynamic therapeutic agent and a conjugated drug.

IPC Classes  ?

• C07D 515/18 - Bridged systems
• C07D 487/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 31/12 - Antivirals

Abstract

The present application relates to the field of biomedicine, and in particular to a small-molecular phosphorus or sulfur-containing macrocycle which has better immunomodulatory activity and selectivity. The present invention further provides a use of the small-molecular phosphorus or sulfur-containing macrocycle for preventing or treating a TLR7-related disease, and a use as a vaccine adjuvant and a photodynamic therapeutic agent.

IPC Classes  ?

• C07D 473/00 - Heterocyclic compounds containing purine ring systems
• C07D 473/40 - Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
• C07F 9/547 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
• C07F 9/28 - Phosphorus compounds with one or more P—C bonds
• C07F 9/141 - Esters of phosphorous acids
• A61P 37/02 - Immunomodulators
• A61P 37/04 - Immunostimulants

Abstract

The present application relates to the field of biomedicine, and in particular, to a small-molecule polyaryl-containing macrocyclic compound which has better immunoregulation activity and selectivity. The present invention further provides a use of the small-molecule polyaryl-containing macrocyclic compound for preventing or treating TLR7-related diseases, and a use of the small-molecule polyaryl-containing macrocyclic compound as a vaccine adjuvant and a photodynamic therapeutic agent.

IPC Classes  ?

• C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

An exosome derived from a birch raw material. The exosome is a nanovesicle having a particle size of about 40-400 nm, preferably about 85-350 nm, and more preferably about 100-250 nm, and has an irregular hemispherical or disc-shaped shape. A method for preparing an exosome from a birch raw material, comprising the following steps: (1) pretreating a birch raw material to obtain a pretreated solution; (2) centrifuging the pretreated solution one or more times to obtain a crude centrifugal extract; and (3) enriching the crude centrifugal extract to obtain an exosome.

IPC Classes  ?

• C12N 5/04 - Plant cells or tissues
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61Q 19/08 - Anti-ageing preparations

Abstract

A composition of Malus niedzwetzkyana Dieck and Prunus cerasifera Ehrhart, wherein the weight ratio of Malus niedzwetzkyana Dieck to Prunus cerasifera Ehrhart is 1:10-10:1. The composition has a synergistic effect in terms of preventing and-or treating atherosclerosis. The product forms of the composition of Malus niedzwetzkyana Dieck and Prunus cerasifera Ehrhart include a fruit juice, a jam, a fruit powder, oral liquid products, capsules, tablets, etc.

IPC Classes  ?

• A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 21/12 - MarmaladesJamsJelliesOther similar fruit or vegetable compositionsSimulated fruit products derived from fruit or vegetable solids
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• A23L 2/02 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof containing fruit or vegetable juices
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

An early-diagnosis system of Parkinson's disease based on exosomal synuclein. In the experiments of patients, it is found that in comparison with a healthy control group, the content of α-synuclein in the total exosome of plasma slightly increases in patients with RBD, and significantly increases in patients with PD. The content of α-synuclein in the central nervous system-derived exosome in the plasma significantly increases in both patients with RBD and PD, which is valuable for early diagnosis; and the content of α-synuclein in the toal exosome in the plasma increases along with the progress of the disease, which is valuable for predicting the progress of diseases. The purpose of non-invasive, efficient and early diagnosis of Parkinson's disease is achieved by means of blood-derived markers, it is of great significance for the early diagnosis of Parkinson's disease, the accuracy of diagnosis can be improved, and certain auxiliary guiding significance is provided for early clinical intervention and reduction of later disability.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided are a biomarker related to Parkinson's disease (PD) and an application thereof. Specifically, fungi, in particular Saccharomyces cerevisiae, can be used as a biomarker for PD diagnosis. Also provided is a detection method for fungi, in particular Saccharomyces cerevisiae. The biomarker and the detection method therefor can be used for auxiliary display of biological information related to PD, in particular early PD, can be used for assisting in distinguishing PD from essential tremor (ET), and can also be used for identifying a PD patient in a prodromal phase, the PD patient in the prodromal phase being a sleep behavior disorder (RBD) patient having the possibility of progressing to PD. Also provided are a kit, a system and a related application. The method can be independently used as a clinical auxiliary diagnosis method, and can also be used as a joint composite index for clinical auxiliary diagnosis.

IPC Classes  ?

• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12R 1/865 - Saccharomyces cerevisiae

Abstract

The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a glucose cotransporter-2 inhibitor (SGLT-2) inhibitor (e.g., canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin and tofogliflozin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

IPC Classes  ?

• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and an a-glucosidase inhibitor (e.g., acarbose, acarbose derivative, voglibose, miglitol and the like). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 31/133 - Amines, e.g. amantadine having hydroxy groups, e.g. sphingosine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/20 - Pills, lozenges or tablets
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a sulfonylurea compound (e.g., glibenclamide, gliclazide, glipizide, gliquidone and glimepiride). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

IPC Classes  ?

• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a thiazolidinedione compound (e.g., rosiglitazone, pioglitazone and the like). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 9/20 - Pills, lozenges or tablets

Abstract

The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a DPP-4 inhibitor (e.g., sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, trelagliptin and omarigliptin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 9/20 - Pills, lozenges or tablets

Abstract

A composition of Malus neidzwetzkyana Dieck and Prunus cerasifera Ehrhart having antithrombotic efficacy. The weight ratio of Malus neidzwetzkyana Dieck to Prunus cerasifera Ehrhart is 1: 10-10: 1. The animal experiments in zebrafish and mouse show that the composition of Malus neidzwetzkyana Dieck and Prunus cerasifera Ehrhart has synergistic effects in terms of antithrombotic efficacy, and the antithrombotic efficacy of the composition is superior to that of Malus neidzwetzkyana Dieck or Prunus cerasifera Ehrhart used alone. Product forms of the composition of Malus neidzwetzkyana Dieck and Prunus cerasifera Ehrhart include fruit juice, fruit jam, lyophilized powder, oral liquid products, capsules, tablets, etc. The combination of the composition of Malus neidzwetzkyana Dieck and Prunus cerasifera Ehrhart with drugs also has certain synergistic effects.

IPC Classes  ?

• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A23L 2/02 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof containing fruit or vegetable juices
• A23L 21/12 - MarmaladesJamsJelliesOther similar fruit or vegetable compositionsSimulated fruit products derived from fruit or vegetable solids
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

A composition of niedzwetzky's apple and prunus cerasifera having a blood lipid-lowering effect. The weight ratio of niedzwetzky's apple to prunus cerasifera is 1:10-10:1. Animal experiments of zebrafishes and mice show that the composition of niedzwetzky's apple and prunus cerasifera has a synergetic effect on lowering the blood lipid, and the blood lipid-lowering effect of the composition is better than that obtained by separately using niedzwetzky's apple or prunus cerasifera. Product forms of the composition of niedzwetzky's apple and prunus cerasifera comprise fruit juice, jam, freeze-dried powder, oral liquid, capsule, tablet, and the like. The composition of niedzwetzky's apple and prunus cerasifera also has a certain synergetic effect when used in combination with a medication.

IPC Classes  ?

• A23L 2/02 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof containing fruit or vegetable juices
• A23P 10/20 - AgglomeratingGranulatingTabletting
• A23G 3/36 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition
• A23P 10/28 - TablettingMaking food bars by compression of a dry powdered mixture
• C12G 3/00 - Preparation of other alcoholic beverages
• A61P 3/06 - Antihyperlipidemics

Abstract

Provided is a Malus niedzwetzkyana Dieck and Prunus cerasifera Ehrhart composition having the effect of lowering blood sugar, wherein the weight ratio of the Malus niedzwetzkyana Dieck to the Prunus cerasifera Ehrhart is 1:10-10:1. Further provided is the use of the composition in the preparation of drugs (such as traditional Chinese medicine and Chinese patent medicine), ordinary foods or health-care foods, wherein the drugs (such as traditional Chinese medicine and Chinese patent medicine), ordinary foods or health-care foods are used for lowering blood sugar or for preventing and/or treating glycemic diseases.

IPC Classes  ?

• A23L 2/02 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof containing fruit or vegetable juices
• A23L 33/26 - Polyol polyesters, e.g. sucrose polyestersSynthetic sugar polymers, e.g. polydextrose
• A23L 2/52 - Adding ingredients

Abstract

The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a biguanide compound (e.g., metformin, metformin hydrochloride, buformin, and phenformin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes, for lipid-lowering and weight-loss, and the like.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• C07J 73/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

Disclosed is a method for improving sleep quality or alleviating sleep disorders, the method comprising allowing a subject in need thereof to drink drinking water that contains specific contents and types of minerals. Further disclosed is use of drinking water/food or medicine containing specific contents and types of minerals for improving sleep quality or alleviating sleep disorders.

IPC Classes  ?

• C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
• A23L 2/52 - Adding ingredients

Abstract

Provided are a linker represented by Formula I or I′, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease. Provided are a linker represented by Formula I or I′, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.

IPC Classes  ?

• C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 207/40 - 2,5-Pyrrolidine-diones
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Abstract

The present application relates to a linker containing arylnitro, an antibody-drug conjugate the linker and use of the linker, as well as a pharmaceutical composition comprising the antibody-drug conjugate and use of the antibody-drug conjugate for treatment and/or prevention of a disease

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 38/07 - Tetrapeptides
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents
• C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07D 207/452 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
• C07D 233/94 - Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
• C07D 307/71 - Nitro radicals attached in position 5
• C07D 333/44 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms attached in position 5
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to a fermented birch sap and a method for producing it, wherein the fermented birch sap is obtained by fermentation using birch sap as a substrate and Inonotus obliquus as a strain; the method comprises the step of fermentation using birch sap as a substrate and Inonotus obliquus as a strain.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/9728 - Fungi, e.g. yeasts
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• A61Q 19/08 - Anti-ageing preparations
• C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
• C12P 7/22 - Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Abstract

A skin topical composition having efficacy of promoting wound healing and/or scar repair, comprising (A) a concentrated birch sap, and (B) one or more of Sanguisorba root extract, Coptis root extract, Arnebia extract, allantoin, Salvia miltiorrhiza extract, Astragalus extract, pearl powder and Asiaticoside, wherein the concentration multiple of the concentrated birch sap is about 1.2-6 times, preferably about 1.5-5 times, more preferably about 1.5-3 times.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/30 - Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
• A61K 36/481 - Astragalus (milkvetch)
• A61K 36/537 - Salvia (sage)
• A61K 36/718 - Coptis (goldthread)
• A61K 36/739 - Sanguisorba (burnet)
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61Q 19/00 - Preparations for care of the skin
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/7024 - Esters of saccharides
• A61K 35/618 - Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs

Abstract

The present invention relates to the field of food and drugs, specifically to a use of a Malus niedzwetskyana product for inhibiting blood clot formation. The Malus niedzwetskyana product comprises a drug, a regular food product or a health food product, such as: fresh fruit, fruit juice, jam, freeze-dried powder, pressed candy, oral solution, capsules, etc. of Malus niedzwetskyana. Animal testing has shown that Malus niedzwetskyana products provide good blood clot formation inhibiting effects in both zebrafish and mice, are superior to regular apple products, and achieve a synergistic effect in combination with antithrombotic drugs.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 31/05 - Phenols
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn

Abstract

An application of a cherry plum product in inhibiting thrombosi. The cherry plum product comprises: jam, dried fruit, fruit preserves, fruit juice, fruit powder, fruit wine, candy, pastry, oral liquid, and fresh cherry plum fruit. The cherry plum product can be used in combination with a drug for preventing and/or treating thrombotic diseases to prepare a combined product or composition for preparing a drug for preventing and/or treating thrombotic diseases.

IPC Classes  ?

• A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A23L 21/12 - MarmaladesJamsJelliesOther similar fruit or vegetable compositionsSimulated fruit products derived from fruit or vegetable solids
• A23L 2/04 - Extraction of juices
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• C12G 3/04 - Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs

Abstract

A mixed birch sap, comprising two or more birch saps from different origins. In addition, also provided are use of the mixed birch sap in a skin care cosmetic composition and a skin care cosmetic composition comprising the mixed birch sap, in particular a moisturizing cosmetic composition, a whitening cosmetic composition, an anti-wrinkle cosmetic composition, and an anti-inflammatory cosmetic composition.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A combination product containing limonoid (and a derivative, ester, a stereoisomer, salt or prodrug thereof that are pharmaceutically acceptable) and an α-glucosidase inhibitor (acarbose, acarbose derivative, voglibose, miglitol and the like). The combination product is used for treating and/or preventing diabetes-related diseases and the like.

IPC Classes  ?

• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The present invention relates to a combination product containing a limonin compound (and a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof) and a thiazolidinedione (for example rosiglitazone, pioglitazone and so on). The present invention also relates to uses of the combination product, such as in the treatment and/or prevention of diabetes-related diseases.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

A combination product comprising limonoids (and pharmaceutically-acceptable derivatives, esters, stereoisomers, salts or prodrugs thereof) and a sodium-glucose co-transporter-2 (SGLT-2) inhibitors (such as canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin). The present invention also relates to the use of the combination product in treating and/or preventing diseases related to diabetes.

IPC Classes  ?

• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a combination product containing a limonoid (and pharmaceutically acceptable derivatives, esters, stereoisomers, salts or prodrugs thereof) and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, trelagliptin and omarigliptin). The present invention also relates to use of the combination product in the treatment and/or prevention of diseases associated with diabetes and so on.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

A combination product containing a limonin compound (and a pharmaceutically acceptable derivative, an ester, a stereoisomer, and a salt or prodrug thereof) and a sulfonylurea drug (such as glibenclamide, gliclazide, glipizide, gliquidone, and glimepiride). The combination product is used for treatment and/or prevention of diabetes-related diseases and the like.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

An external composition for skin having an enhanced anti-eczema effect. The external composition for skin comprises (A) concentrated birch juice, wherein the concentration factor of the concentrated birch juice is about 1.05-8 times, preferably about 1.1-4 times, and more preferably about 1.2-2 times; and (B) one or more substances selected from avena sativa kernel extract, prinsepia utilis royle oil, marigold extract, allantoin, bisabolol, ceramide, panthenol, glycerol, and squalene.

IPC Classes  ?

• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 17/00 - Drugs for dermatological disorders
• A61K 8/31 - Hydrocarbons
• A61K 8/34 - Alcohols
• A61K 8/42 - Amides
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/67 - Vitamins
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61Q 19/00 - Preparations for care of the skin
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

Abstract

The use of concentrated birch sap in an anti-hair loss hair growth composition, and an anti-hair loss hair growth composition, which comprises the concentrated birch sap.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 7/00 - Preparations for affecting hair growth

Abstract

An enhanced anti-aging cosmetic composition, comprising (A) a concentrated birch sap, the concentration factor thereof being about 1.05 - 8 times, preferably 1.1 - 4 times, and more preferably 1.2 - 2 times, and (B) one or more materials selected from a polypeptide, sodium hyaluronate, retinol, retinene, retinol palmitate, tocopherol, ubiquinone and adenosine.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61K 8/67 - Vitamins
• A61K 8/73 - Polysaccharides
• A61Q 19/08 - Anti-ageing preparations

Abstract

Use of concentrated birch sap in a whitening cosmetic composition, and a concentrated birch sap-containing whitening cosmetic composition.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin

Abstract

An enhanced hair loss prevention and hair growth promotion composition, comprising a combination of (A) a concentrated birch sap and (B) any one or more of a ginger extract, a Fallopia multiflora root extract, a ginseng extract, a green tea extract, a Platycladus orientalis extract, an Angelica sinensis extract, an Astragalus propinquus extract, an Eclipta alba extract, a Betula platyphylla sprout extract, a white Betula platyphylla leaf extract, adenosine, nicotinamide, and tripeptide-1 copper. The concentration factor of the concentrated birch sap is about 1.2 - 8 times, preferably about 1.5 - 6 times, and more preferably about 1.5 - 5 times.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61K 8/9761 - Cupressaceae [Cypress family], e.g. juniper or cypress
• A61K 8/67 - Vitamins
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61Q 7/00 - Preparations for affecting hair growth
• A61Q 5/02 - Preparations for cleaning the hair

Abstract

Disclosed is a use of a concentrated birch sap in a moisturizing cosmetic composition, and a moisturizing cosmetic composition containing the concentrated birch sap.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin

Abstract

Fermented brich juice, a preparation method therefor and use thereof in a composition for external application to skin. The fermented brich juice is obtained by fermenting inonotus obliquus serving as bacterial strains and brich juice serving as a substrate.

IPC Classes  ?

• C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• A61Q 19/08 - Anti-ageing preparations
• C12R 1/645 - Fungi

Abstract

A concentrated birch sap, having a concentration factor of 1.05 - 8 times. The concentrated birch sap has a significant anti-aging effect. The present invention also relates to an anti-aging cosmetic composition comprising the concentrated birch sap. The cosmetic composition exhibits a significant anti-aging effect.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations

Abstract

A skin composition for external use having an anti-inflammatory effect, including concentrated birch sap, a degree of concentration being 1.05-8 times, preferably 1.1-4 times.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 17/00 - Drugs for dermatological disorders
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin

Abstract

An enhanced whitening cosmetic composition, comprising: (A) concentrated birch juice; and (B) one or more substances selected from arbutin, tranexamic acid, nicotinamide, glabridin, ascorbic acid, ascorbyl glucoside, L-ascorbyl dipalmitate, and ascorbyl tetraisopalmitate, wherein the concentration multiple of the concentrated birch juice is 1.05-6 times.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/67 - Vitamins
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin

Abstract

The present invention relates to the use of birch juice in the preparation of a topical skin composition with an anti-eczema effect, and a topical skin composition with an anti-eczema effect, which composition comprises birch juice.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 17/00 - Drugs for dermatological disorders
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin

Abstract

Disclosed is an external skin composition having an anti-acne effect, comprising (A) a concentrated birch sap, the concentration factor thereof being about 1.1 - 8 times, preferably about 1.2 - 4 times, and more preferably about 1.2 - 2 times, and (B) one or more materials selected from salicylic acid, malic acid, an aloe extract, a green tea extract, PCA zinc, allantoin, sodium hyaluronate and nicotinamide.

IPC Classes  ?

• A61K 36/886 - Aloeaceae (Aloe family), e.g. aloe vera
• A61K 36/896 - Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
• A61P 17/10 - Anti-acne agents
• A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/67 - Vitamins
• A61K 8/73 - Polysaccharides
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61Q 19/00 - Preparations for care of the skin
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/60 - Salicylic acidDerivatives thereof

Abstract

A composition with an acne removal effect for external application to skin, comprising concentrated birch juice at a concentration factor of about 1.1 to 10 times, preferably about 1.2 to 8 times, and more preferably about 1.5 to 6 times.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61Q 19/00 - Preparations for care of the skin
• A61P 17/10 - Anti-acne agents

Abstract

An external skin treatment composition with enhanced anti-inflammatory effect comprises: (A) a concentrated birch sap having a concentration of about 1.05-8 times, preferably about 1.1-4 times, more preferably about 1.2-2 times, and (B) one or more substances selected from oat kernel extract, panthenol, allantoin, bisabolol and dipotassium glycyrrhizinate.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61Q 19/00 - Preparations for care of the skin

Abstract

An enhanced moisture-retaining cosmetic composition, comprising (A) concentrated birch sap, the concentration factor being about 1.05-8 times, preferably 1.1-4 times, and most preferably 1.2-2 times; and (B) one or multiple substances selected from sodium hyaluronate, allantoin, ceramide, betaine and polyols.

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/73 - Polysaccharides
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/68 - Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/34 - Alcohols
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to a composition containing a limonin compound and a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof and a biguanide compound; the biguanide compound may be metformin or metformin hydrochloride, buformin or phenformin, and so on. The present invention further relates to a use of the composition in the treatment and/or prevention of diseases associated with diabetes, fat-reduction weight loss and so on.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• C07J 73/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/04 - AnorexiantsAntiobesity agents